As Graphite and Graphene Demand Skyrockets, Graphjet Technology Tees Up IPO

Graphjet Technology, an emerging company producing graphite and graphene – critical raw materials for a variety of consumer products including EV batteries – is readying plans to go public following a merger agreement with Energem Corp. a Special Purpose Acquisition Company (SPAC). The merger, which was announced August 2, 2022, will allow Graphjet to become a U.S. Corporation and list on the NASDAQ under the ticker symbol “GTI.”

Graphjet’s patent-pending breakthrough technology transforms an abundant and renewable waste product – palm kernel shells – into highly valued artificial graphene and graphite at a price that is 80 to 90 percent lower than the current market price. Graphjet’s “green” technology is more advanced than other manufacturers of graphite and graphene, and reduces carbon emissions and pollutions.

Malaysia is the second largest producer of palm oil and the waste by-product palm kernel shells in the world, second only to Indonesia. It is estimated that Malaysia generates approximately 5 million tons of dried palm kernel shells annually, making it a sustainable and recyclable source for the production of high-quality synthetic graphite and graphene. Malaysia is where Graphjet currently manufactures graphite and graphene.

We are very excited to prepare for our listing on the NASDAQ stock exchange,” said Graphjet CEO Aiden Lee. “As a U.S. company, Graphjet will be able to provide the graphene critical to products like EV batteries, semiconductors, and biomedical devices, all at a cost of approximately 80 to 90 percent less than what is currently being manufactured in China.” Mr. Lee added, “We are thrilled to be able to ramp up the manufacturing using an innovative, sustainable natural resource under our proprietary process.”

The anticipated pro forma enterprise value upon completion of Graphjet’s IPO is $1.49 billion. Approximately $115 million is expected to be used for business expansion purposes, including building a manufacturing plant. The company currently outsources its manufacturing operation. Once the new plant is built, Graphjet will be able to double its current capacity and increase its profit margin.

On September 12, 2022, subsequent to announcing its planned merger with Energem, Graphjet announced a collaboration with the prestigious Massachusetts Institute of Technology (MIT). As a member of MIT’s Industrial Liaison Program, Graphjet joins more than 240 leading enterprises such as Apple, BMW, Hyundai, Misubishi, Samsung and other companies who are also in collaborative partnerships with MIT. The collaboration reaffirms Graphjet’s pioneering position in the graphite and graphene industry.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Graphjet Technology Sdn. Bhd.. (2022, October 13). As Graphite and Graphene Demand Skyrockets, Graphjet Technology Tees Up IPO. AZoCleantech. Retrieved on July 18, 2024 from https://www.azocleantech.com/news.aspx?newsID=32419.

  • MLA

    Graphjet Technology Sdn. Bhd.. "As Graphite and Graphene Demand Skyrockets, Graphjet Technology Tees Up IPO". AZoCleantech. 18 July 2024. <https://www.azocleantech.com/news.aspx?newsID=32419>.

  • Chicago

    Graphjet Technology Sdn. Bhd.. "As Graphite and Graphene Demand Skyrockets, Graphjet Technology Tees Up IPO". AZoCleantech. https://www.azocleantech.com/news.aspx?newsID=32419. (accessed July 18, 2024).

  • Harvard

    Graphjet Technology Sdn. Bhd.. 2022. As Graphite and Graphene Demand Skyrockets, Graphjet Technology Tees Up IPO. AZoCleantech, viewed 18 July 2024, https://www.azocleantech.com/news.aspx?newsID=32419.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.